Ignite Creation Date:
2024-05-05 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00113763
Status:
COMPLETED
Last Update Posted:
2022-11-07
First Post:
2005-06-10
Brief Title:
Evaluating Panitumumab ABX-EGF Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
An Open-label Randomized Phase 3 Clinical Trial of ABX-EGF Plus Best Supportive Care Versus Best Supportive Care in Subjects With Metastatic Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine that panitumumab using the proposed regimen will safely increase progression free survival in patients with metastatic colorectal cancer who have failed available treatment options ie patients who developed progressive disease or relapsed while on or after prior fluoropyrimidine irinotecan and oxaliplatin chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None